Directly targeting transcriptional dysregulation in cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Targeting intracellular signaling pathways has improved cancer patient outcomes.
• Therapeutic resistance emerges rapidly due to pathway redundancy and mutations.
• Existing therapies face limitations from bypass signaling and downstream mutations.

Purpose of the Study:

• To propose transcriptional regulators as superior therapeutic targets in cancer.
• To address the challenge of therapeutic resistance in cancer treatment.
• To advocate for a shift towards targeting transcriptional regulation.

Main Methods:

• Review of kinase signaling pathways and resistance mechanisms.
• Analysis of the role of transcriptional regulators in cancer phenotype and maintenance.
• Argument for targeting transcriptional regulators based on their inherent resistance to bypass.

Main Results:

• Dysregulation of key transcriptional regulators defines and maintains cancer phenotypes.
• Transcriptional regulators are less susceptible to bypass mutations and clonal heterogeneity.
• Targeting transcriptional regulation offers a promising strategy against therapeutic resistance.

Conclusions:

• Transcriptional regulators represent a more robust therapeutic target class than kinase signaling pathways.
• Developing drugs targeting transcriptional regulation is crucial for overcoming cancer resistance.
• A renewed focus on transcriptional regulation is essential for advancing cancer therapy.